Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

LEGION Hinge Safety and Efficacy Study

NCT02445443 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2015-06-30
Last updated
2024-11-27

Condition(s) studied

Knee Arthroplasty, Total

Investigational drug(s) / intervention(s)

LEGION Hinge Knee System

LEGION Hinge Knee System: All enrolled/treated subjects will receive the LEGION Hinge Knee System.

Study summary

The purpose of the current investigation is to assess the safety and efficacy of a new hinged revision knee device. This device is designed to provide efficient, reproducible reconstructions with optimal limb and implant alignment, durable implant fixation, and functional outcomes that increasingly approach those of primary Total Knee Arthroplasty (TKA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Subject has gross knee instability resulting from loss of collateral ligament function, gross bone loss, comminuted fractures of the proximal tibia or distal femur, rheumatoid arthritis, post-traumatic arthritis, osteoarthritis, degenerative arthritis, failed osteotomies, unicompartmental replacement or total knee replacement, or absent or incompetent posterior cruciate ligament and one or both of the collateral ligaments * Subject has a failed primary or revision knee replacement * Subject is 18-80 years of age * Subject is skeletally mature in Investigator's judgment i.e., subject is not actively growing or does not have immature bones for any reason * Subject has met an acceptable preoperative medical clearance and is free of or treated for cardiac, pulmonary, hematological, infection or other conditions that would pose excessive operative risk * Subject is willing to sign and date an IRB/EC-approved consent form * Subject plans to be available through the five (5) year postoperative follow-up * If of child bearing potential, Subject reports she is not pregnant nor plans to become pregnant during the study * Subject agrees to follow the study protocol Exclusion Criteria: * Subject is receiving the study device as a primary knee replacement * Subject has presence of malignant tumor, metastatic, or neoplastic disease * Subject is not expected to return to normal ambulatory function (i.e., morbid obesity or other limiting co-morbidities) * Subject is pregnant or plans to become pregnant during the course of the study * Subject has conditions that may interfere with the revision arthroplasty survival or outcome (i.e., Paget's or Charcot-Marie-Tooth disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease) * Subject has known (Subject reported) metal hypersensitivity * Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in this study * Subject has BMI\>45 * Subject is participating in any other pharmaceutical, biologic, or medical device clinical investigation or has been treated with an investigational product in the past 30 days * Subject is facing current or impending incarceration * Subject is not a good candidate for the study based on Investigator opinion

Primary outcome measure(s)

  • Original Knee Society Clinical Score© (KSCS) — 1 year
    The original Knee Society Score© (KSS) is subdivided into two parts. One part is the Knee Society Clinical Score (KSCS) and the other part is the Knee Society Functional Score (KSFS). The KSCS will be administered at the pre-operative visit and all follow-up visits. The purpose of administering this assessment is to determine the statistical clinical improvement over time which may be compared to literature at 1 and 2 years.
  • Revision — Up to 5 years
    Revision, for any reason, will be assessed throughout the subject's participation in the study.

Trial sites (7)

FacilityCityRegionStatus
University of Iowa Hospitals Iowa City Iowa
NYU Hospital for Joint Diseases New York New York
Oregon Health and Science University Portland Oregon
Fremantle Hospital Fremantle Western Australia
UZ Leuven campus Pellenberg Pellenberg Belgium
Concordia Hip and Knee Institute Winnipeg Manitoba
University Hospital Mutua de Terrassa Terrassa Barcelona
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02445443 on ClinicalTrials.gov ↗ ← All trials in the USA